en Endocrinology Endocrinology Original Article Original Article <span style="font-size:14px;"><span style="font-family:Times New Roman;"><span style="color:#0000ff;"><em><strong>Background:</strong></em></span>&nbsp; Diabetic neuropathic pain (DNP) is a common complication of diabetes and has a profound effect on patients quality of life. Therefore. The purpose of the present study was to compare the analgesic effects of duloxetine and nortryptiline in the management of patients with diabetic neuropathy.<br> <span style="color:#0000ff;"><em><strong>Methods:</strong> </em></span>This was a randomized, double-blind, parallel-group, placebo-controlled trial in subjects with a proven diagnosis of DM and suffered from neuropathic pain<strong>. </strong>Patients were recruited in this study from 20 February 2016 (first patient, first visit) to 22 June 2017 (last patient, last visit), including 5 weeks follow-up. A diagnosis of DNP was based on history, clinical examination, Nerve conduction velocity and Diabetic neuropathy symptom score (more than one point).<br> <span style="color:#0000ff;"><em><strong>Results:</strong></em></span> Both drugs reduced pain when compared with placebo. A significant VAS reduction from 6.4 at baseline to 3.75 at endpoint was observed in the duloxetine group. However, there was no significant difference in the efficacy between nortriptyline and duloxetine based on patient&#39;s visual analogue scale (VAS) (p>0.05). No clinically significant changes or serious adverse events were found among treatment groups including changes in vital signs, laboratory assessments, physical examination or electrocardiograms. The decrease in the mean pain intensity was significantly greater in the duloxetine and nortriptyline group compared to the placebo group both in the primary analysis and in the by-visit analysis (p<0.003)<br> <strong><span style="color:#0000ff;"><em>Conclusions:</em></span> </strong>The present study demonstrates the safety and effectiveness of both duloxetine and nortriptyline in the management of DNP.</span></span> diabetic peripheral neuropathy, nortriptyline, duloxetine, diabetes, pain 29 34 http://caspjim.com/browse.php?a_code=A-10-142-2&slc_lang=en&sid=1 Mohammadali Bayani bayanima49@yahoo.com 100319475328460027310 100319475328460027310 No Department of Internal Medicine, Babol University of Medical sciences, Babol, Iran Babak Moazammi babak_m@gmail.com 100319475328460027311 100319475328460027311 Yes Babol Universtiy of Medical sciences, Babol, Iran Farshad Fadaee-Jouybari Fadaeejouybari _f@gmail.com 100319475328460027312 100319475328460027312 No Babol Universtiy of Medical sciences, Babol, Iran Mansour Babaei babaeim47@yahoo.com 100319475328460027313 100319475328460027313 No Department of Internal Medicine, Babol University of Medical sciences, Babol, Iran Alijan Ahmadi-Ahangar ahmadiahangaralijan@yahoo.com 100319475328460027314 100319475328460027314 No Mobility Impairment Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran Payam Saadat sepanta1968@yahoo.com 100319475328460027315 100319475328460027315 No Mobility Impairment Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran